**Novel T-cell receptor program expands Cellantra’s oncology pipeline and is designed to recognize a cancer-associated MAGE-C1 antigen presented by HLA-A*02:01**
Cellantra, an in vivo gene therapy and next-generation immuno-oncology biotechnology company, today announced the discovery and development of a novel T-cell receptor (TCR) candidate directed against MAGE-C1, also known as CT7, a cancer-testis antigen associated with several malignancies.
The newly developed TCR is designed to recognize a **MAGE-C1-derived peptide presented by HLA-A*02:01**, enabling antigen-specific recognition at the surface of cancer cells. MAGE-C1 has previously been identified as a potentially attractive immunotherapy target, particularly in multiple myeloma, where MAGE-C1 expression has been extensively documented. Published research has also demonstrated that HLA-A2-restricted MAGE-C1 epitopes can be recognized by antigen-specific CD8+ T cells, supporting the biological rationale for MAGE-C1-directed T-cell therapies.
A New TCR Candidate Designed for Precision Cancer Recognition
Cellantra developed the MAGE-C1 TCR program using its integrated computational immunology and protein-engineering platform to identify and optimize TCR architectures capable of selectively engaging the intended peptide-HLA complex.
The lead candidate has successfully progressed through the company’s computational discovery and structural-evaluation stage. Cellantra is advancing the program through additional specificity, off-target, safety and experimental functional validation before determining the appropriate path toward formal preclinical development.
The program is being developed with several core objectives:
- highly selective recognition of the intended MAGE-C1 peptide-HLA complex;
- strong TCR-target interaction compatible with effective T-cell activation;
- discrimination against unrelated peptide-HLA complexes;
- systematic evaluation of potential peptide cross-reactivity and off-target recognition; and
- compatibility with future engineered T-cell and in vivo immune-cell programming strategies.
MAGE-C1 is a member of the cancer-testis antigen family, a class of tumor-associated antigens whose restricted normal-tissue expression and re-expression in malignancies have made them of substantial interest for cancer immunotherapy. MAGE-C1 has been particularly associated with multiple myeloma and has also been investigated in other MAGE-C1-positive malignancies.
Expanding the Cellantra Precision Immuno-Oncology Pipeline
The MAGE-C1 program represents an expansion of Cellantra’s broader effort to develop programmable, antigen-directed cancer therapies.
Rather than relying exclusively on targets located on the exterior of tumor cells, TCR-based approaches can potentially recognize peptides derived from intracellular proteins after those peptides are processed and displayed by HLA molecules on the cell surface. This substantially expands the universe of cancer-associated proteins potentially accessible to immune-based therapeutics.
Cellantra believes that combining precision TCR discovery with advanced gene-delivery and immune-cell engineering technologies could ultimately provide a framework for addressing cancers that remain difficult to treat using conventional surface-antigen approaches.
“Our MAGE-C1 TCR program reflects the broader strategy behind Cellantrah: identify biologically compelling cancer targets, engineer highly selective molecular recognition systems, and ultimately integrate those systems with technologies capable of programming therapeutic activity in vivo,” the company said. “MAGE-C1 is an especially interesting antigen because of its cancer-associated expression profile and the existing biological evidence supporting T-cell recognition of MAGE-C1-derived peptide-HLA complexes.”
Building Toward Experimental and Preclinical Validation
Cellantra will next focus on experimental confirmation of target binding, functional T-cell activity, selectivity and comprehensive off-target assessment.
The company intends to use these studies to determine whether the candidate meets its internal criteria for advancement into broader preclinical development.
The MAGE-C1 TCR candidate is investigational and has not been approved for therapeutic use. Clinical safety or efficacy has not been established.
About Cellantra
Cellantra is a biotechnology company developing next-generation in vivo gene therapy and precision immuno-oncology technologies. The company is building a pipeline spanning engineered T-cell receptor programs, intracellular cancer-targeting therapeutics, in vivo immune-cell programming and advanced nucleic-acid delivery technologies.
Cellantra’s research strategy combines computational molecular design, targeted delivery and experimental validation with the long-term objective of transforming complex biological discoveries into new therapeutic modalities.
Cellantra — Make the World a Better Place.
This press release contains forward-looking statements regarding Cellantra’s research programs, technology platforms, development plans and potential therapeutic applications. These statements involve scientific, technical, regulatory and development uncertainties. Computational results and early preclinical findings may not predict subsequent experimental, preclinical or clinical outcomes. Cellantra’s investigational programs have not been demonstrated to be safe or effective in humans, and no assurance can be given that any program will successfully advance into or through clinical development.
